93 related articles for article (PubMed ID: 16481338)
1. An updated physiologically based pharmacokinetic model for hexachlorobenzene: incorporation of pathophysiological states following partial hepatectomy and hexachlorobenzene treatment.
Lu Y; Lohitnavy M; Reddy MB; Lohitnavy O; Ashley A; Yang RS
Toxicol Sci; 2006 May; 91(1):29-41. PubMed ID: 16481338
[TBL] [Abstract][Full Text] [Related]
2. A clonal growth model: time-course simulations of liver foci growth following penta- or hexachlorobenzene treatment in a medium-term bioassay.
Ou YC; Conolly RB; Thomas RS; Xu Y; Andersen ME; Chubb LS; Pitot HC; Yang RS
Cancer Res; 2001 Mar; 61(5):1879-89. PubMed ID: 11280742
[TBL] [Abstract][Full Text] [Related]
3. Quantitative analysis of liver GST-P foci promoted by a chemical mixture of hexachlorobenzene and PCB 126: implication of size-dependent cellular growth kinetics.
Lu Y; Lohitnavy M; Reddy M; Lohitnavy O; Eickman E; Ashley A; Gerjevic L; Xu Y; Conolly RB; Yang RS
Arch Toxicol; 2008 Feb; 82(2):103-16. PubMed ID: 17874069
[TBL] [Abstract][Full Text] [Related]
4. Stochastic simulation of hepatic preneoplastic foci development for four chlorobenzene congeners in a medium-term bioassay.
Ou YC; Conolly RB; Thomas RS; Gustafson DL; Long ME; Dobrev ID; Chubb LS; Xu Y; Lapidot SA; Andersen ME; Yang RS
Toxicol Sci; 2003 Jun; 73(2):301-14. PubMed ID: 12700395
[TBL] [Abstract][Full Text] [Related]
5. Development, evaluation and use of a pharmacokinetic model for hexachlorobenzene.
Yesair DW; Feder PI; Chin AE; Naber SJ; Kuiper-Goodman T; Scott CS; Robinson PE
IARC Sci Publ; 1986; (77):297-318. PubMed ID: 3596717
[TBL] [Abstract][Full Text] [Related]
6. Development of a physiologically based pharmacokinetic model for deltamethrin in the adult male Sprague-Dawley rat.
Mirfazaelian A; Kim KB; Anand SS; Kim HJ; Tornero-Velez R; Bruckner JV; Fisher JW
Toxicol Sci; 2006 Oct; 93(2):432-42. PubMed ID: 16831841
[TBL] [Abstract][Full Text] [Related]
7. A physiologically based pharmacodynamic analysis of hepatic foci within a medium-term liver bioassay using pentachlorobenzene as a promoter and diethylnitrosamine as an initiator.
Thomas RS; Conolly RB; Gustafson DL; Long ME; Benjamin SA; Yang RS
Toxicol Appl Pharmacol; 2000 Jul; 166(2):128-37. PubMed ID: 10896854
[TBL] [Abstract][Full Text] [Related]
8. NTP Toxicology and Carcinogenesis Studies of Methyleugenol (CAS NO. 93-15-2) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2000 Jul; 491():1-412. PubMed ID: 12563349
[TBL] [Abstract][Full Text] [Related]
9. Physiologically based pharmacokinetic modeling of cyclotrimethylenetrinitramine in male rats.
Krishnan K; Crouse LC; Bazar MA; Major MA; Reddy G
J Appl Toxicol; 2009 Oct; 29(7):629-37. PubMed ID: 19629953
[TBL] [Abstract][Full Text] [Related]
10. A physiologically based pharmacokinetic model for fluoride uptake by bone.
Rao HV; Beliles RP; Whitford GM; Turner CH
Regul Toxicol Pharmacol; 1995 Aug; 22(1):30-42. PubMed ID: 7494900
[TBL] [Abstract][Full Text] [Related]
11. PBPK models in risk assessment--A focus on chloroprene.
DeWoskin RS
Chem Biol Interact; 2007 Mar; 166(1-3):352-9. PubMed ID: 17324392
[TBL] [Abstract][Full Text] [Related]
12. Determination of age and gender differences in biochemical processes affecting the disposition of 2-butoxyethanol and its metabolites in mice and rats to improve PBPK modeling.
Corley RA; Grant DM; Farris E; Weitz KK; Soelberg JJ; Thrall KD; Poet TS
Toxicol Lett; 2005 Mar; 156(1):127-61. PubMed ID: 15705493
[TBL] [Abstract][Full Text] [Related]
13. A comparison of physiologically based pharmacokinetic model predictions and experimental data for inhaled ethanol in male and female B6C3F1 mice, F344 rats, and humans.
Pastino GM; Asgharian B; Roberts K; Medinsky MA; Bond JA
Toxicol Appl Pharmacol; 1997 Jul; 145(1):147-57. PubMed ID: 9221833
[TBL] [Abstract][Full Text] [Related]
14. Physiologically based pharmacokinetic modeling of deltamethrin: development of a rat and human diffusion-limited model.
Godin SJ; DeVito MJ; Hughes MF; Ross DG; Scollon EJ; Starr JM; Setzer RW; Conolly RB; Tornero-Velez R
Toxicol Sci; 2010 Jun; 115(2):330-43. PubMed ID: 20200215
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic model for chronic inhalation of 2-butoxyethanol.
Lee KM; Dill JA; Chou BJ; Roycroft JH
Toxicol Appl Pharmacol; 1998 Dec; 153(2):211-26. PubMed ID: 9878592
[TBL] [Abstract][Full Text] [Related]
16. A physiologically based pharmacokinetic model for ethylene oxide in mouse, rat, and human.
Fennell TR; Brown CD
Toxicol Appl Pharmacol; 2001 Jun; 173(3):161-75. PubMed ID: 11437638
[TBL] [Abstract][Full Text] [Related]
17. High-fat diet enhances the accumulation of hexachlorobenzene (HCB) by pregnant rats during continuous exposure to HCB.
Nakashima Y; Ikegami S
J Agric Food Chem; 2003 Mar; 51(6):1628-33. PubMed ID: 12617596
[TBL] [Abstract][Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
19. Sexual dimorphism in the regulation of liver connexin32 transcription in hexachlorobenzene-treated rats.
Plante I; Cyr DG; Charbonneau M
Toxicol Sci; 2007 Mar; 96(1):47-57. PubMed ID: 17150971
[TBL] [Abstract][Full Text] [Related]
20. Mechanistic modeling of hepatic transport from cells to whole body: application to napsagatran and fexofenadine.
Poirier A; Funk C; Scherrmann JM; Lavé T
Mol Pharm; 2009; 6(6):1716-33. PubMed ID: 19739673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
